Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

Source: 
Drugs.com
snippet: 

The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms.